The purpose of this study is to investigate the
use of the medication Ondansetron as an adjunctive or add-on therapy to
existing anti-psychotic medication in the treatment of schizophrenia
symptoms. Ondansetron is a well established medication which is approved
in Australia for the treatment of drug-induced nausea and vomiting.
However, various case studies and clinical studies have shown
Ondansetron to also be effective in the treatment of symptoms associated
with persistent schizophrenia.This study will examine whether Ondansetron in combination with standard antipsychotic medication is more effective in improving the symptoms of schizophrenia than antipsychotic medication alone.
Contact
Mr Daniel Grice on (03) 9076 6581or email participate.maprc@monash.edu
Ethics Committee Project Number: 145/10
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.